Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses
Primary Purpose
Mitral Valve Stenosis and Insufficiency, Atrial Fibrillation
Status
Unknown status
Phase
Phase 4
Locations
Russian Federation
Study Type
Interventional
Intervention
Dabigatran Etexilate
Warfarin
Sponsored by
About this trial
This is an interventional prevention trial for Mitral Valve Stenosis and Insufficiency focused on measuring Atrial Fibrillation, Mitral Valve Stenosis, Mitral Valve Insufficiency, Dabigatran, Biological Prosthesis, Mitral Valve Replacement, Cox-Maze Procedure
Eligibility Criteria
Inclusion Criteria:
- mitral valve disease;
- atrial fibrillation;
- mitral valve prosthetic replacement with concomitant Cox-Maze Procedure;
- 18-75 years of age;
- signed informed consent form.
Exclusion Criteria:
- mechanical valve replacement;
- repeated mitral valve surgery;
- coronary artery hemodynamically significant stenoses;
- ventricular arrhythmias;
- creatinine clearance <50 ml/min;
- HAS-BLED score >3;
- previous stroke or transient ischemic attack;
- liver diseases;
- neoplasia;
- pregnancy;
- simultaneous antiplatelet therapy;
- allergic reactions on Dabigatran or Warfarin;
- cognitive disorders.
Sites / Locations
- Research Institute for Complex Problems of Cardiovascular Diseases
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Dabigatran
Warfarin
Arm Description
Dabigatran etexilate 150 mg by mouth every 12 hours for a year
Warfarin by mouth every 24 hours in a dose providing international normalized ratio (INR) 2.5-3.5 for a year
Outcomes
Primary Outcome Measures
Thrombosis
Thrombosis of prosthetic valve, transient ischemic attack, stroke, myocardial infarction, pulmonary and systemic thromboembolic events
Secondary Outcome Measures
Major Bleeding
Massive symptomatic intracranial, intraocular, retroperitoneal, intraarticular, pericardial bleeding or intramuscular bleeding associated with compressive syndrome
Full Information
NCT ID
NCT03183843
First Posted
June 8, 2017
Last Updated
June 8, 2017
Sponsor
Research Institute for Complex Problems of Cardiovascular Diseases, Russia
1. Study Identification
Unique Protocol Identification Number
NCT03183843
Brief Title
Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses
Official Title
The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Unknown status
Study Start Date
June 29, 2016 (Actual)
Primary Completion Date
June 30, 2018 (Anticipated)
Study Completion Date
December 1, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Research Institute for Complex Problems of Cardiovascular Diseases, Russia
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The efficacy and safety of anticoagulation therapy using dabigatran in comparison with warfarin will be evaluated in patients with atrial fibrillation after mitral valve prosthetic replacement concomitant with Cox-Maze procedure.
Detailed Description
Patients with prosthetic mitral valves need a long-term anticoagulation therapy. After mitral valve replacement using mechanical prostheses warfarin is administrated during the whole life. Biological prostheses allows do discontinue anticoagulation 3 months after surgery in the absence of other risk factors of thrombosis especially atrial fibrillation. The common approach to patients with mitral valve disease and atrial fibrillation is mitral valve prosthetic replacement concomitant to Cox-Maze procedure. This allows to maintain sinus rhythm in 65-80% of patients. In the study the safety and efficacy of dabigatran in comparison with warfarin will be evaluated after the mitral valve surgery and Cox-Maze procedure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mitral Valve Stenosis and Insufficiency, Atrial Fibrillation
Keywords
Atrial Fibrillation, Mitral Valve Stenosis, Mitral Valve Insufficiency, Dabigatran, Biological Prosthesis, Mitral Valve Replacement, Cox-Maze Procedure
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dabigatran
Arm Type
Active Comparator
Arm Description
Dabigatran etexilate 150 mg by mouth every 12 hours for a year
Arm Title
Warfarin
Arm Type
Active Comparator
Arm Description
Warfarin by mouth every 24 hours in a dose providing international normalized ratio (INR) 2.5-3.5 for a year
Intervention Type
Drug
Intervention Name(s)
Dabigatran Etexilate
Other Intervention Name(s)
Pradaxa
Intervention Description
Dabigatran Etexilate 150 mg capsules for oral administration twice a day
Intervention Type
Drug
Intervention Name(s)
Warfarin
Other Intervention Name(s)
Coumadin
Intervention Description
Warfarin 2.5 mg tablets for oral administration once a day
Primary Outcome Measure Information:
Title
Thrombosis
Description
Thrombosis of prosthetic valve, transient ischemic attack, stroke, myocardial infarction, pulmonary and systemic thromboembolic events
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Major Bleeding
Description
Massive symptomatic intracranial, intraocular, retroperitoneal, intraarticular, pericardial bleeding or intramuscular bleeding associated with compressive syndrome
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
mitral valve disease;
atrial fibrillation;
mitral valve prosthetic replacement with concomitant Cox-Maze Procedure;
18-75 years of age;
signed informed consent form.
Exclusion Criteria:
mechanical valve replacement;
repeated mitral valve surgery;
coronary artery hemodynamically significant stenoses;
ventricular arrhythmias;
creatinine clearance <50 ml/min;
HAS-BLED score >3;
previous stroke or transient ischemic attack;
liver diseases;
neoplasia;
pregnancy;
simultaneous antiplatelet therapy;
allergic reactions on Dabigatran or Warfarin;
cognitive disorders.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yevgeny V Grigoriev, M.D., Ph.D.
Organizational Affiliation
Research Institute for Complex Problems of Cardiovascular Diseases
Official's Role
Study Chair
Facility Information:
Facility Name
Research Institute for Complex Problems of Cardiovascular Diseases
City
Kemerovo
ZIP/Postal Code
650061
Country
Russian Federation
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26384981
Citation
Yadlapati A, Groh C, Malaisrie SC, Gajjar M, Kruse J, Meyers S, Passman R. Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. Clin Res Cardiol. 2016 Mar;105(3):268-72. doi: 10.1007/s00392-015-0919-z. Epub 2015 Sep 18.
Results Reference
background
PubMed Identifier
19683642
Citation
Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet. 2009 Aug 15;374(9689):565-76. doi: 10.1016/S0140-6736(09)60780-7.
Results Reference
background
Learn more about this trial
Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses
We'll reach out to this number within 24 hrs